MIS416

Last updated

MIS416 is an experimental drug developed by Innate Immunotherapeutics which underwent clinical trials to treat secondary progressive multiple sclerosis. It is derived from the bacteria that causes acne and targets myeloid cells through TLR9 and NOD2. [1] [2] [3] [4] In one of its first rounds of clinical trials, the drug was shown to be "safe and well tolerated", with 80% of secondary-progressive multiple sclerosis patients exhibiting more than 30% improvement in at least one area of their MS status. [1] However, Phase II clinical trials were unable to prove that the drug provided a benefit to patients. It is also being researched as a potential treatment for cancer.

Contents

Development

MIS416 is a microparticle derived from the cytoskeleton of P. acnes , [5] a species of bacteria present on the skin of most adults that causes acne. [6]

MIS416 was originally developed as a vaccine adjuvant, a component of vaccines that helps to activate an immune response against the vaccine target. Bacteria-derived microparticles have several advantages over traditional adjuvants related both to their size and biological properties. [5] [7]

Because MIS416 is engulfed by immune cells, it is being investigated as an immunotherapy-based treatment for solid tumors. [2]

The drug was used to treat multiple sclerosis under a compassionate use law in New Zealand before clinical trials began. [5] It is administered as an intravenous infusion. In 2017, clinical trials in people with secondary progressive multiple sclerosis failed to meet the primary endpoint of slowed progression of the disease. [2]

Phase II trial and aftermath

On June 22, 2017, Innate Immunotherapeutics announced that clinical trials undertaken to evaluate the efficacy of MIS416 in managing secondary progressive multiple sclerosis (SPMS) had "failed to show any clinically meaningful benefit or statistical significance". [8] [9] As a result, the company's stock dropped by 92 percent [8] and crashed on the Australian Securities Exchange. [9]

US Congressman Chris Collins, a member of the company's board of directors and 17-percent stock holder, was subsequently indicted on charges of insider trading in connection with the poor clinical trial results. [8] Collins had allegedly obtained word from the company about the results and informed his son, Cameron Collins, who immediately sold his US stock. Cameron allegedly tipped off shareholder Stephen Zarsky, who informed three others, thus preventing a total loss of $768,000 in stocks. Zarsky was indicted together with Collins and his son. [8]

Related Research Articles

Multiple sclerosis Disease that damages the myelin sheaths around nerves

Multiple sclerosis (MS) is a demyelinating disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged. This damage disrupts the ability of parts of the nervous system to transmit signals, resulting in a range of signs and symptoms, including physical, mental, and sometimes psychiatric problems. Specific symptoms can include double vision, blindness in one eye, muscle weakness and trouble with sensation or coordination. MS takes several forms, with new symptoms either occurring in isolated attacks or building up over time. Between attacks, symptoms may disappear completely; however, permanent neurological problems often remain, especially as the disease advances.

Minocycline chemical compound

Minocycline, sold under the brand name Minocin among others, is a tetracycline antibiotic used to treat a number of bacterial infections such as pneumonia. It is generally less preferred than the tetracycline doxycycline. It is also used for the treatment of acne and rheumatoid arthritis. It is taken by mouth or applied to the skin.

<i>Cutibacterium acnes</i> species of bacterium

Cutibacterium acnes is the relatively slow-growing, typically aerotolerant anaerobic, Gram-positive bacterium (rod) linked to the skin condition of acne; it can also cause chronic blepharitis and endophthalmitis, the latter particularly following intraocular surgery. Its genome has been sequenced and a study has shown several genes can generate enzymes for degrading skin and proteins that may be immunogenic.

A cancer vaccine is a vaccine that either treats existing cancer or prevents development of cancer. Vaccines that treat existing cancer are known as therapeutic cancer vaccines. Some/many of the vaccines are "autologous", being prepared from samples taken from the patient, and are specific to that patient.

Lipid A lipid component of lipopolysaccharide endotoxins of gram-negative bacteria

Lipid A is a lipid component of an endotoxin held responsible for the toxicity of gram-negative bacteria. It is the innermost of the three regions of the lipopolysaccharide (LPS), also called endotoxin molecule, and its hydrophobic nature allows it to anchor the LPS to the outer membrane. While its toxic effects can be damaging, the sensing of lipid A by the human immune system may also be critical for the onset of immune responses to gram-negative infection, and for the subsequent successful fight against the infection.

Natalizumab pharmaceutical drug

Natalizumab, sold under the brand name Tysabri among others, is a medication used to treat multiple sclerosis and Crohn's disease. It is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin. It is given by intravenous infusion every 28 days. The drug is believed to work by reducing the ability of inflammatory immune cells to attach to and pass through the cell layers lining the intestines and blood–brain barrier. Natalizumab has proven effective in treating the symptoms of both diseases, preventing relapse, vision loss, cognitive decline and significantly improving quality of life in people with multiple sclerosis, as well as increasing rates of remission and preventing relapse in multiple sclerosis.

Tcelna is an anti-T cell vaccine being studied in multiple sclerosis (MS). As of 2016 it is in phase II trials.

Ocrelizumab, sold under the brand name Ocrevus, is a pharmaceutical drug for the treatment of multiple sclerosis (MS). It is a humanized anti-CD20 monoclonal antibody. It targets CD20 marker on B lymphocytes and hence is an immunosuppressive drug. Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds.

In immunology, an adjuvant is a substance that potentiates and/or modulates the immune responses to an antigen to improve them. The word "adjuvant" comes from the Latin word adiuvare, meaning to help or aid. "An immunologic adjuvant is defined as any substance that acts to accelerate, prolong, or enhance antigen-specific immune responses when used in combination with specific vaccine antigens."

Malaria vaccine vaccine that is used to prevent malaria

A malaria vaccine is a vaccine that is used to prevent malaria. The only approved vaccine as of 2015 is RTS,S, known by the trade name Mosquirix. It requires four injections, and has a relatively low efficacy. Due to this low efficacy, the World Health Organization (WHO) does not recommend the routine use of the RTS,S vaccine in babies between 6 and 12 weeks of age.

Mycobacterium vaccae is a nonpathogenic species of the Mycobacteriaceae family of bacteria that lives naturally in soil. Its generic name originates from the Latin word, vacca (cow), since the first Mycobacterium strain was cultured from cow dung in Austria. Mycobacterium vaccae originates from the Ugandan Lang'o District, where locals claimed that a "muddy substance had the power to cure a number of ailments". Research areas being pursued with regard to killed Mycobacterium vaccae vaccine include immunotherapy for allergic asthma, cancer, depression, leprosy, psoriasis, dermatitis, eczema and tuberculosis.

Hepatitis B vaccine vaccine against Hepatitis B

Hepatitis B vaccine is a vaccine that prevents hepatitis B. The first dose is recommended within 24 hours of birth with either two or three more doses given after that. This includes those with poor immune function such as from HIV/AIDS and those born premature. It is also recommended that health-care workers be vaccinated. In healthy people routine immunization results in more than 95% of people being protected.

Research in multiple sclerosis may find new pathways to interact with the disease, improve function, curtail attacks, or limit the progression of the underlying disease. Many treatments already in clinical trials involve drugs that are used in other diseases or medications that have not been designed specifically for multiple sclerosis. There are also trials involving the combination of drugs that are already in use for multiple sclerosis. Finally, there are also many basic investigations that try to understand better the disease and in the future may help to find new treatments.

Dirucotide chemical compound

Dirucotide (also known as MBP8298) was developed by two research scientists (Dr. Kenneth G. Warren, MD, FRCP(C) & Ingrid Catz, Senior Scientist) at the University of Alberta for the treatment of Multiple Sclerosis (MS). Dirucotide is a synthetic peptide that consists of 17 amino acids linked in a sequence identical to that of a portion of human myelin basic protein (MBP). The sequence of these 17 amino acids is

A hepatitis C vaccine, a vaccine capable of protecting against the hepatitis C virus (HCV), is not yet available. Although vaccines exist for hepatitis A and hepatitis B, development of an HCV vaccine has presented challenges. No vaccine is currently available, but several vaccines are currently under development.

Ozanimod chemical compound

Ozanimod, sold under the brand name Zeposia, is an immunomodulatory drug for the treatment of relapsing multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. It acts as a sphingosine-1-phosphate (S1P) receptor agonist, sequestering lymphocytes to peripheral lymphoid organs and away from their sites of chronic inflammation. Shortly after Receptos, Inc. developed ozanimod, they were acquired by Celgene for $7.2 billion. The most common adverse reactions are upper respiratory infection, hepatic transaminase elevation, orthostatic hypotension, urinary tract infection, back pain, and hypertension.

Siponimod chemical compound

Siponimod, sold under the brand name Mayzent, is a selective sphingosine-1-phosphate receptor modulator for oral use that is used for multiple sclerosis (MS). It is intended for once-daily oral administration.

This page describes the process and status of pharmaceuticals for treating multiple sclerosis (MS).

Innate Immunotherapeutics (INNM) was a biopharmaceutical company, previously known as Virionyx, with headquarters in Sydney, Australia and a branch in Auckland, New Zealand. Their focus in 2009 was the "development of a new generation of immune response modifier for potential use in the treatment of a range of infectious diseases, certain cancers, and as a novel cellular and humoral adjuvant, " and developed a proprietary multiple sclerosis drug, MIS416. In April 2009 the firm changed its name to Innate Immunotherapeutics to reflect their focus on the development of MIS416, and moved their headquarters from Auckland, New Zealand to Sydney, Australia. On June 22, 2017, Innate Immunotherapeutics announced that the MIS416 clinical trials undertaken to evaluate its efficacy in managing secondary progressive multiple sclerosis (SPMS), had "failed to show any clinically meaningful benefit or statistical significance." These findings resulted in the stocks crashing on the Australian Securities Exchange (ASX).

Otilimab is a fully human antibody which has been developed by the biotechnology company MorphoSys. It can also be referred to as HuCAL antibody, HuCAL standing for Human Combinatorial Antibody Library and being a technology used to generate monoclonal antibodies. Otilimab is directed against the granulocyte-macrophage colony stimulating factor (GM-CSF), a monomeric glycoprotein functioning as a cytokine promoting both proliferation and activation of macrophages and neutrophils.

References

  1. 1 2 "Innate Immunotherapeutics: Acne Offers Real Hope for MS Treatment". Australasian Biotechnology. 23 (3): 55. October 2013. ISSN   1036-7128.
  2. 1 2 3 "Drug Profile: MIS 416". adisinsight.springer.com. 27 June 2018. Retrieved 29 August 2018.
  3. ↑ "Results Announced from Phase 2 Trial of MIS416". National Multiple Sclerosis Society. 27 June 2017.
  4. ↑ "Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis". United States National Library of Medicine. 28 August 2014. Retrieved 29 August 2018.
  5. 1 2 3 Shirani, Afsaneh; Okuda, Darin T.; Stüve, Olaf (2016). "Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis". Neurotherapeutics. 13 (1): 58–69. doi:10.1007/s13311-015-0409-z. ISSN   1933-7213. PMC   4720678 . PMID   26729332.
  6. ↑ Brüggemann, Holger; Henne, Anke; Hoster, Frank; Liesegang, Heiko; Wiezer, Arnim; Strittmatter, Axel; Hujer, Sandra; Dürre, Peter; Gottschalk, Gerhard (30 July 2004). "The Complete Genome Sequence of Propionibacterium Acnes, a Commensal of Human Skin". Science. 305 (5684): 671–673. doi:10.1126/science.1100330. ISSN   0036-8075. PMID   15286373. S2CID   26252335.
  7. ↑ Girvan, Rebecca C.; Knight, Deborah A.; o'Loughlin, Chris J.; Hayman, Colin M.; Hermans, Ian F.; Webster, Gill A. (10 January 2011). "MIS416, a non-toxic microparticle adjuvant derived from Propionibacterium acnes comprising immunostimulatory muramyl dipeptide and bacterial DNA promotes cross-priming and Th1 immunity". Vaccine. 29 (3): 545–557. doi:10.1016/j.vaccine.2010.10.040. ISSN   0264-410X. PMID   21034827.
  8. 1 2 3 4 "New York Congressman Chris Collins indicted on insider trading charges". CBS News . 8 August 2018. Retrieved 29 August 2018.
  9. 1 2 LaMotta, Lisa (June 27, 2017). "Innate becomes the latest loser in MS". BioPharma Dive. Retrieved August 8, 2018.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.